CLAIMS

1. Use of a composition comprising 2',4'-dihydroxy-3',6'-dimethoxychalcone or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the prevention and/or treatment of a disease associated with IL-23 expression, wherein 2',4'-dihydroxy-3',6'-dimethoxychalcone down-regulates gene expression of IL-23 and wherein said disease associated with IL-23 expression is not a cancer.

2. The use according to claim 1, wherein said composition further comprises a pharmaceutically acceptable carrier.

3. The use according to claim 1 or 2, wherein said composition further comprises at least one additional therapeutic agent.

4. The use according to any of claims 1 to 2, wherein 2',4'-dihydroxy-3',6'-dimethoxychalcone or said pharmaceutically acceptable salt thereof is the sole therapeutic agent in said composition.

5. The use according to any one of claims 1 to 4, wherein said composition is to be administered via a local, enteral, or parenteral route, preferably via a topical, oral, intraperitoneal, intravenous, intradermal, subcutaneous, intra-articular, or mucosal route, more preferably via an oral or intraperitoneal route.

6. The use according to any one of claims 1 to 5, wherein said composition is to be administered at least once per day.

7. The use according to any one of claims 1 to 6, wherein 2',4'-dihydroxy-3',6'-dimethoxychalcone or said pharmaceutically acceptable salt thereof is to be administered at a dose comprised between 1 mg/kg and 10 mg/kg per day.

8. The use according to any one of claims 1 to 7, wherein said disease associated with IL-23 expression is selected from an autoimmune disease and/or an inflammatory disease including non-infectious inflammatory respiratory diseases and/or a neurodegenerative disease other than Alzheimer's.

9. The use according to claim 8, wherein said autoimmune disease is selected from rheumatologic autoimmune diseases, gastrointestinal and liver autoimmune diseases, vasculitis, renal autoimmune diseases, dermatological autoimmune diseases, hematologic autoimmune diseases, atherosclerosis, uveitis, autoimmune ear diseases, Raynaud's syndrome, diseases associated with organ transplantation and autoimmune endocrine diseases such as diabetes.

10. The use according to claim 8, wherein:

said inflammatory disease is selected from arthritis, rheumatoid arthritis, acute gout arthritis, osteoarthritis, an inflammatory bone disease; an inflammatory lung disease, preferably asthma, adult respiratory distress syndrome, or chronic obstructive airway disease; Behcet's disease; an inflammatory disease of the eye preferably corneal dystrophy, trachoma, onchocerciasis, uveitis, sympathetic ophthalmitis or endophthalmitis; a chronic inflammatory disease of the gums preferably gingivitis or periodontitis; tuberculosis; leprosy; an inflammatory disease of the kidney preferably a uremic complication, glomerulonephritis or nephrosis; an inflammatory disorder of the skin, preferably psoriasis; a chronic demyelinating diseases of the nervous system; infectious meningitis; encephalomyelitis; Parkinson's disease; Huntington's disease; amyotrophic lateral sclerosis; an immune-complex vasculitis; systemic lupus erythematosus (SLE); an inflammatory disease of the heart, preferably cardiomyopathy, coronary thrombosis, ischemic heart disease hypercholesterolemia, or atherosclerosis; preeclampsia; schizophrenia; chronic liver failure, or brain or spinal cord trauma; endometriosis and/or

said neurodegenerative disease is selected from among migraine headache, trigeminal neuralgia, myasthenia gravis, a demyelinating disease, preferably acute transverse myelitis; an extrapyramidal and cerebellar disorder; a hyperkinetic movement disorder, preferably Huntington's Chorea or senile chorea; a drug-induced movement disorder, preferably a disorder induced by drugs which block CNS dopamine receptors; a hypokinetic movement disorder, preferably Parkinson's disease; progressive supranucleo Palsy; a structural lesion of the cerebellum; a spinocerebellar degenerations, preferably spinal ataxia, Friedreich's ataxia, a cerebellar cortical degeneration, or a multiple systems degeneration; a systemic disorder, preferably Refsum's disease, abetalipoproteinemia, ataxia, telangiectasia, or mitochondrial multi-system disorder; a disorder of the motor unit, preferably a neurogenic muscular atrophy and more preferably amyotrophic lateral sclerosis; Down's Syndrome in middle age; Diffuse Lewy body disease; Senile Dementia of Lewy body type; Wernicke-Korsakoff syndrome; chronic alcoholism; Creutzfeldt-Jakob disease; Subacute sclerosing panencephalitis, Rasmussen's encephalitis, Huntington's

disease, Hallerrorden-Spatz disease; Dementia pugilistica; neurotraumatic injury; inflammatory pain; autism; depression; head trauma, stroke; cognitive disorders; epilepsy; macular degeneration; and/or

said non-infectious inflammatory respiratory disease is selected from the group consisting of interstitial lung disease, cystic fibrosis, pulmonary oedema, chronic obstructive pulmonary disease, asthma, allergic alveolitis, restrictive lung disease, fibrosis, lupus erythematosus, systemic scleroderma or sarcoidosis, and rhinitis.

11. The use according to any one of claims 1 to 7, wherein said disease associated with IL-23 expression is selected from graft-versus-host disease (GvHD), psoriasis, acute gout arthritis, rheumatoid arthritis, amyotrophic lateral sclerosis, macular degeneration and endometriosis.